Clinical Research Directory

Inclusion Criteria: * Aged 18-70 years old (including 18 and 70 years old) with newly diagnosed favorable-risk AML (2022 ELN risk group classification). * Achieved CR1 after 1-2 cycles of standard chemotherapy. * Completed 4-6 cycles of consolidation chemotherapy (including at least 2 cycles of high-dose Cytarabine HDAC regimem). * At the end of consolidation treatment, bone marrow examination confirmed in CR1, flow cytometry MRD negative, but molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by \> 3 log, but still detectable. * Performance status score of 0-2 (ECOG). * Liver function: ALT and AST ≤ 2.5 times the upper limit of normal, bilirubin ≤ 2 times the upper limit of normal. * Kidney function: Creatinine ≤ 1.5 times the upper limit of normal. Exclusion Criteria: * Acute promyelocytic leukemia (APL). * AML with normal karyotype and bZIP intramolecular mutations in CEBPA. * ≥ CR2 status. * Patients strongly demanding transplantation, and with indications for transplantation but not eligible for transplantation. * Uncontrolled active infection. * Severe organ dysfunction. * Pregnancy. * Unwillingness to undergo interferon treatment. * Previous hyperthyroidism or hypothyroidism. * Participation in other clinical trials within one month.